Difficult transition from a new oral anticoagulant to parenteral anticoagulant in an overweight female

2015 ◽  
Vol 37 (5) ◽  
pp. e135-e136
Author(s):  
F. N. Smith ◽  
M. J. Nash ◽  
J. Thachil
Keyword(s):  
Oral Anticoagulant ◽  
New Oral Anticoagulant ◽  
Difficult Transition

scholarly journals A case of heparin induced thrombocytopenia managed by Rivaroxaban

2021 ◽  
Author(s):  
Ali Eshraghi ◽  
Faeze Keihanian
Keyword(s):  
Cardiac Surgery ◽  
Oral Anticoagulant ◽  
Heparin Induced Thrombocytopenia ◽  
Heparin Administration ◽  
New Oral Anticoagulant ◽  
Increased Risk

Heparin-induced thrombocytopenia (HIT) is an immunogenic disorder. It can lead to thrombocytopenia and a hypercoagulated state with an increased risk for new thrombosis. We here reported a 49-year-old man with previous cardiac surgery and heparin administration, treated by new oral anticoagulant agent, Rivaroxaban.

Antidotes for the new oral anticoagulant drugs!

2019 ◽  
Vol 2 (3) ◽  
pp. 78
Author(s):  
Jawed Fareed ◽  
Fakiha Siddiqui ◽  
Eduardo Ramacciotti ◽  
Alfonso Tafur
Keyword(s):  
Oral Anticoagulant ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs

scholarly journals The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients

Medicine ◽  
2019 ◽  
Vol 98 (48) ◽  
pp. e18205
Author(s):  
Yi-yue Gui ◽  
Song Zou ◽  
Wen-long Yang ◽  
Shen-zhen Gong ◽  
Zhi-fu Cen ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Renal Function ◽  
Oral Anticoagulant ◽  
Efficacy And Safety ◽  
New Oral Anticoagulant ◽  
The Impact

Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs

2010 ◽  
Vol 104 (12) ◽  
pp. 1083-1084 ◽  
Author(s):  
Charles Marc Samama ◽  
Nadia Rosencher ◽  
Paul Jacques Zufferey
Keyword(s):  
Phase Ii ◽  
Oral Anticoagulant ◽  
Phase Ii Trials ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs

scholarly journals Régi és új orális antikoagulánsok hazai alkalmazása pitvarfibrillációban

2017 ◽  
Vol 158 (39) ◽  
pp. 1545-1549
Author(s):  
János Tomcsányi ◽  
Balázs Salfer ◽  
Bence Nagy
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Oral Anticoagulant ◽  
Oral Anticoagulant Therapy ◽  
Real Life ◽  
Vitamin K Antagonist ◽  
Anticoagulant Treatment ◽  
Oral Anticoagulant Treatment ◽  
New Oral Anticoagulant ◽  
Method Analysis

Abstract: Introduction: Despite a progress in the management of patients with atrial fibrillation this arrhythmia is one of the major causes of stroke, heart failure, sudden death and cardiovascular morbidity. Oral anticoagulation with vitamin K antagonist or non-vitamin K antagonist markedly reduces stroke and mortality in atrial fibrillation patients. Aim: To estimate the real-life vitamin K antagonist and non-vitamin K antagonist oral anticoagulant treatment in past years in Hungary. Method: Analysis of the National Health Insurance Administation database for atrial fibrillation (BNO: I48) between 2010–2015. We assumed that AF patient would turn to health care provides at least once either as inpatients or outpatients in a 5-year period. The patient was accepted as adherent after 6 months therapy and at least 80% oral anticoagulant prescription. Results: The prevalence of AF in Hungary is 3%. The mortality rate of AF 7%–10% per year. The adherence of the old oral anticoagulant treatment was 55%, but it was 69% among patient treated by “new” oral anticoagulant treatment. However, one third of the patients are not treated by effective old or new oral anticoagulant treatment. Conclusions: We need more effort to improve the effective and high adherence oral anticoagulant therapy in our country. Orv Hetil. 2017; 158(39): 1545–1549.

Sign in / Sign up

Export Citation Format

Share Document